Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy : Analysis of 919 Cases Outside Clinical Trials
Copyright © 2022 Morabito, Zamagni, Conticello, Pavone, Palmieri, Bringhen, Galli, Mangiacavalli, Derudas, Rossi, Ria, Catalano, Tacchetti, Mele, Vincelli, Martino, Vigna, Bruzzese, Mendicino, Botta, Mele, Pantani, Rocchi, Garibaldi, Cascavilla, Ballanti, Tripepi, Frigeri, Falcone, Cangialosi, Reddiconto, Farina, Barone, Rizzello, Iaccino, Mimmi, Curci, Gamberi, Musto, De Stefano, Musso, Petrucci, Offidani, Di Raimondo, Boccadoro, Cavo, Neri and Gentile..
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS KRd/EloRd ) and progression-free survival (PFS, PRS KRd/EloRd ) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis-therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no difference between the two strategies. The multivariate model identified a significant progression/death risk increase for ISS III (HR = 1.37; P = 0.002), >3 previous lines of therapies (HR = 1.67; P < 0.0001), older age (HR = 1.64; P < 0.0001), and prior lenalidomide exposure (HR = 1.35; P = 0.003). Three risk SRS KRd/EloRd categories were generated: low-risk (134 cases, 16.5%), intermediate-risk (467 cases, 57.3%), and high-risk categories (213 cases, 26.2%). The 1- and 2-year OS probability rates were 92.3% and 83.8% for the low-risk (HR = 1, reference category), 81.1% and 60.6% (HR = 2.73; P < 0.0001) for the intermediate-risk, and 65.5% and 42.5% (HR = 4.91; P < 0.0001) for the high-risk groups, respectively. Notably, unlike the low-risk group, which did not cross the median timeline, the OS median values were 36.6 and 18.6 months for the intermediate- and high-risk cases, respectively. Similarly, three PRS KRd/EloRd risk categories were engendered. Based on such grouping, 338 (41.5%) cases were allocated in the low-, 248 (30.5%) in the intermediate-, and 228 (28.0%) in the high-risk groups. The 1- and 2-year PFS probability rates were 71.4% and 54.5% for the low-risk (HR = 1, reference category), 68.9% and 43.7% (HR = 1.95; P < 0.0001) for the intermediate-risk, and 48.0% and 27.1% (HR = 3.73; P < 0.0001) for the high-risk groups, respectively. The PFS median values were 29.0, 21.0, and 11.7 months for the low-, intermediate-, and high-risk cases. This analysis showed 2.7- and 4.9-fold increased risk of death for the intermediate- and high-risk cases treated with KRd/EloRd as salvage therapy. The combined progression/death risks of the two categories were increased 1.3- and 2.2-fold compared to the low-risk group. In conclusion, SRS KRd/EloRd and PRS KRd/EloRd may represent accessible and globally applicable models in daily clinical practice and ultimately represent a prognostic tool for RRMM patients who received KRd or EloRd.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 12(2022) vom: 27., Seite 890376 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Carfilzomib |
|---|
| Anmerkungen: |
Date Revised 05.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2022.890376 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34443723X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34443723X | ||
| 003 | DE-627 | ||
| 005 | 20231226205101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.890376 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM34443723X | ||
| 035 | |a (NLM)35924160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morabito, Fortunato |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy |b Analysis of 919 Cases Outside Clinical Trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Morabito, Zamagni, Conticello, Pavone, Palmieri, Bringhen, Galli, Mangiacavalli, Derudas, Rossi, Ria, Catalano, Tacchetti, Mele, Vincelli, Martino, Vigna, Bruzzese, Mendicino, Botta, Mele, Pantani, Rocchi, Garibaldi, Cascavilla, Ballanti, Tripepi, Frigeri, Falcone, Cangialosi, Reddiconto, Farina, Barone, Rizzello, Iaccino, Mimmi, Curci, Gamberi, Musto, De Stefano, Musso, Petrucci, Offidani, Di Raimondo, Boccadoro, Cavo, Neri and Gentile. | ||
| 520 | |a The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS KRd/EloRd ) and progression-free survival (PFS, PRS KRd/EloRd ) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis-therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no difference between the two strategies. The multivariate model identified a significant progression/death risk increase for ISS III (HR = 1.37; P = 0.002), >3 previous lines of therapies (HR = 1.67; P < 0.0001), older age (HR = 1.64; P < 0.0001), and prior lenalidomide exposure (HR = 1.35; P = 0.003). Three risk SRS KRd/EloRd categories were generated: low-risk (134 cases, 16.5%), intermediate-risk (467 cases, 57.3%), and high-risk categories (213 cases, 26.2%). The 1- and 2-year OS probability rates were 92.3% and 83.8% for the low-risk (HR = 1, reference category), 81.1% and 60.6% (HR = 2.73; P < 0.0001) for the intermediate-risk, and 65.5% and 42.5% (HR = 4.91; P < 0.0001) for the high-risk groups, respectively. Notably, unlike the low-risk group, which did not cross the median timeline, the OS median values were 36.6 and 18.6 months for the intermediate- and high-risk cases, respectively. Similarly, three PRS KRd/EloRd risk categories were engendered. Based on such grouping, 338 (41.5%) cases were allocated in the low-, 248 (30.5%) in the intermediate-, and 228 (28.0%) in the high-risk groups. The 1- and 2-year PFS probability rates were 71.4% and 54.5% for the low-risk (HR = 1, reference category), 68.9% and 43.7% (HR = 1.95; P < 0.0001) for the intermediate-risk, and 48.0% and 27.1% (HR = 3.73; P < 0.0001) for the high-risk groups, respectively. The PFS median values were 29.0, 21.0, and 11.7 months for the low-, intermediate-, and high-risk cases. This analysis showed 2.7- and 4.9-fold increased risk of death for the intermediate- and high-risk cases treated with KRd/EloRd as salvage therapy. The combined progression/death risks of the two categories were increased 1.3- and 2.2-fold compared to the low-risk group. In conclusion, SRS KRd/EloRd and PRS KRd/EloRd may represent accessible and globally applicable models in daily clinical practice and ultimately represent a prognostic tool for RRMM patients who received KRd or EloRd | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a carfilzomib | |
| 650 | 4 | |a elotuzumab | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a prognostic score | |
| 650 | 4 | |a relapsed/refractory | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Zamagni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Conticello, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Pavone, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Bringhen, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Mangiacavalli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Derudas, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ria, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Catalano, Lucio |e verfasserin |4 aut | |
| 700 | 1 | |a Tacchetti, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Mele, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Vincelli, Iolanda Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Enrica Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Vigna, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzese, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Mendicino, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Botta, Cirino |e verfasserin |4 aut | |
| 700 | 1 | |a Mele, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Pantani, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Rocchi, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Garibaldi, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Cascavilla, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Ballanti, Stelvio |e verfasserin |4 aut | |
| 700 | 1 | |a Tripepi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Frigeri, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Falcone, Antonetta Pia |e verfasserin |4 aut | |
| 700 | 1 | |a Cangialosi, Clotilde |e verfasserin |4 aut | |
| 700 | 1 | |a Reddiconto, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Giuliana |e verfasserin |4 aut | |
| 700 | 1 | |a Barone, Marialucia |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzello, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccino, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Mimmi, Selena |e verfasserin |4 aut | |
| 700 | 1 | |a Curci, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Gamberi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Musso, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Petrucci, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Offidani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Raimondo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Boccadoro, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Neri, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 27., Seite 890376 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:27 |g pages:890376 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.890376 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 27 |h 890376 | ||